ArticleMethods in molecular biology (Clifton, N.J.)2026
An Indigenous Workflow for Generating CD19 CAR-T Cells.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FDA-approved CD19 CAR T cell therapy for treating B-cell lineage malignancies gave impetus to the adoptive immune/cell and gene therapy field. Although tested to a considerable extent, side effects such as immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hematotoxicity (ICAHTs), the high cost of the therapy, and often complicated logistics make the accessibility of this CAR therapy far from the reach of many eligible patients. Therefore, the development of a safe, cost-effective, streamlined indigenous workflow for T-cell expansion, transduction, and CAR T-cell characterization is essential in a preclinical as well as clinical setting. We have optimized a method to develop CD19 CAR T cells from peripheral blood T cells from healthy donors. In this chapter, we describe an indigenous protocol for the generation and characterization of CD19 CAR T cells via lentiviral transduction to understand the immunology or possible downstream applications.
Indexed as
Identifiers
41028268What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.